Trial Profile
A Phase III, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Aug 2023
Price :
$35
*
At a glance
- Drugs Omidenepag isopropyl (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Registrational; Therapeutic Use
- Acronyms Spectrum 4
- Sponsors Santen Inc
- 08 Aug 2023 Status changed from active, no longer recruiting to completed.
- 12 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Jun 2019 Planned End Date changed from 17 Oct 2019 to 31 Dec 2019.